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This study aimed to use molecular markers to do surveillance of antimalarial drug 
resistance and inform drug policy. The focus was on sulfadoxine-pyrimethamine drug 
resistance since that was the first-line treatment in Tanzania for an uncomplicated malaria 
infection of Plasmodium falciparum. There are five mutations across two genes that are 
associated with this drug. On the dhfr gene, mutations at the 51 (N51I), 59 (C59R), and 
108 (S108N) position are associated with pyrimethamine drug resistance. On the dhps 
gene, mutations at the 437 (A437G) and 540 (K540E) positions are associated with 
sulfadoxine drug resistance. Samples were collected from Tanzania in 2004, and the 
blood samples analyzed via high resolution melting (HRM). The peaks of each sample 
were compared to reference strains to determine the genotype of each sample. The 
prevalence of 51I, 59R, 108N, 437G, and 540E was 50%, 42.3%, 69.3%, 28.0%, and 0%, 
respectively. Individual genotypes were reported for those samples that were completed 
for all the quintuple mutations (n = 50). For the dhfr gene, 76% had a mutation at the 108 
position, 52% had a mutation at the 51 position, and 42% had a mutant allele at the 59 
position. For the dhps gene, 28% had a mutant genotype at the 437 position, and 0% had 
a mutation at the 540 positions. These prevalence results were like those of other studies. 
However, the individual genotypes differed from other studies. Further research must be 
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 Malaria is a parasitic disease that is transmitted person to person via the bite of an 
infected female Anopheles mosquito. As of 2018, around 228 million cases of malaria 
exist worldwide [1]. Africa carries a disproportionately high percentage of the global 
malaria burden. In 2018, Africa represented about 93% of all malaria cases and about 
94% of malaria deaths [1]. There are 5 species of the parasite that causes malaria in 
humans, of which Plasmodium falciparum and Plasmodium vivax pose the highest risk. 
Plasmodium falciparum is the most virulent strain of Plasmodium and is associated with 
most malaria-related deaths [2]. P. falciparum accounted for about 99% of estimated 
malaria cases in Africa as of 2018 [1]. Certain groups within the population are at a higher 
risk of becoming infected with malaria and developing severe disease than others. These 
groups include children under 5 years old, pregnant women, those would are infected 
with HIV/AIDS, and migrants or travelers to endemic regions [3]. In order to combat a 
Plasmodium infection, antimalarials are used to target proliferative trophozoites and 
schizonts. The current treatment of choice in endemic areas is artemisinin combination 
therapies (ACTs). Artemisinin is used since it blocks the ring stage and sexual parasite 
stage of Plasmodium [4].  
 Drug resistance is defined as the ability of a parasite to survive in the presence of 
drug concentrations that normally destroy parasites of the same species or prevent 
multiplication [5]. There are two types of resistance: relative and complete. Relative drug 
resistance is associated with drug tolerance that will require a higher dose of antimalarials 
to achieve the same level of parasite death. Complete drug resistance is associated with 
parasites' survival beyond the highest dosage of antimalarials that can be tolerated by 
the host. In the absence of drug pressure, drug resistance is thought to emerge de novo 
through spontaneous mutation or gene duplications. In the presence of drug pressure, 
the mutated parasites have a selection advantage that increases the mutated parasites’ 
population size [6]. There are many mechanisms that drug resistance is achieved 
through, such as alterations in drug transport and permeability, drug conversion into a 
form with lower activity, higher expression of the target of the drug, changes to drug target 
that lowers the binding affinity to inhibitor, and the possibility of entering a quiescent state, 
so once the drug concentration is cleared, normal cell cycle progression continues [7]. To 
increase the coverage of larger populations, salt medicated with antimalarial were 
introduced. This was thought to contribute to the rise of the parasite with increased 
tolerance to antimalarial drugs since low concentrations of a drug in the population 
provide optimal conditions for drug resistance to develop. Currently, some resistance 
exists for every antimalarial drug on the market [8]. 
There has been a declining response to antimalarial drugs since their 
implementation. Quinine is one of the oldest antimalarials, and its first use was 
documented in 1631 [8]. Its responsiveness has steadily been declining from the 1970s 
to the 1990s [9]. Chloroquine (CQ) was introduced as a treatment in the 1940s. 
Chloroquine resistance was first recognized at the Thai-Cambodian border in the 1950s 
and spread to the east coast of Africa in 1978 [10]. Mefloquine was introduced in 1977, 
with resistance being reported shortly after in 1982 at the Thai-Myanmar and Thai-
Cambodian borders [11]. Antifolates, such as pyrimethamine, were used as antimalarials 
in the late 1940s and resistance documented soon after its introduction [12]. After this, 
combinations of antifolate drugs began to be used as antimalarials. Sulfadoxine-
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pyrimethamine (SP) replaced CQ as resistance to chloroquine increased. However, 
resistance emerged for SP emerged in Southeast Asia and the Amazon basin in the mid-
1970s, and it spread to Africa in the 1990s [13]. With drugs losing their responsiveness 
to malaria, in 2005, artemisinin-based combination therapies became the first-line 
treatment for uncomplicated Plasmodium falciparum malaria in endemic countries. 
However, in recent years, artemisinin resistance has been noted in the Greater Mekong 
sub-region in Southeast Asia [14].  
Malaria is endemic to most parts of Tanzania and accounts for over 40% of the 
disease burden of the world [15]. In 2003, over 95% of the 37.4 million people at Tanzania 
were at risk for malarial infection [16]. Malaria was also associated with the high rate of 
death among adults in Tanzania from 2003 to 2007 [17]. More than one-third of deaths 
among children under the age of 5 years were caused by malaria [18]. Until 2001, 
chloroquine was used for many years as the first-line treatment for uncomplicated 
malaria. It was preferred by many people since it was cheap and available, and was used 
for self-medication in homes since it had minimal side effects [15]. However, the rapid 
development and transmission of resistance to chloroquine contributed to the change in 
antimalarial treatment policies to sulfadoxine-pyrimethamine (SP). During the blood 
sample collection in 2003, the first-line treatment was SP.  
Sulfadoxine-pyrimethamine (SP) is an antifolate combination-drug that inhibits two 
enzymes in the folate pathway. Sulfadoxine inhibits dihydropteroate synthase (DHPS)  
and targets 7, 8-dihydro-6-hydroxymethylpterin pyrophosphokinase (PPPK). 
Pyrimethamine inhibits dihydrofolate reductase (DHFR) and targets the thymidylate 
synthase (TS) enzyme. Both sulfadoxine and pyrimethamine are mostly active against 
the later developmental stage of asexual parasites [19]. The two targeted enzymes 
targets by the medications are an essential part of the folic acid biosynthesis pathway of 
the parasite [20]. Resistance to SP is associated with unique point mutations in P. 
falciparum DHPS-PPPK and DHFR-TS genes [21]. Amino acid mutations in the dhps 
gene (S436A, A437G, K540E, & A613T/S) are associated with sulfadoxine resistance 
[22]. In vitro sulfadoxine resistance is seemly associated with an amino acid mutation at 
position 437 of the dhps domain from alanine (A) to glycine (G) [A437G]. An increase of 
sulfadoxine resistance is associated with other mutations at positions 540 (lysine to 
glutamic acid), 436 (serine to phenylalanine), and 613 (alanine to serine) [23]. Amino acid 
mutations in the dhfr gene (N51I, C59R, S108N, & I164L) are associated with 
pyrimethamine resistance [24]. In vitro resistance, pyrimethamine resistance is more 
often associated with an amino acid mutation from serine to asparagine at the 108 
positions on the dhfr domain [S108N]. Higher levels of in vitro resistance are due to 
mutations at positions 51 (asparagine to isoleucine), 59 (cysteine to arginine), and 164 
(isoleucine to leucine) [25]. In contrast, in vivo sulfadoxine-pyrimethamine resistance is 
associated with a mutation on the dhfr domain (C59R) and one on the dhps domain 
(K540E) [26]. In Africa, the presence of the quintuple mutant P. falciparum parasites is 
the best marker for SP resistance in the field. The quintuple mutants carry three mutations 
in dhfr (S108N, C59R, N51I) and two mutations in dhps (A437G, K540E) [27].  
A key part of malarial control is monitoring the efficacy of antimalarial drugs. 
Efficacy of antimalarial is assessed through therapeutic efficacy studies (TES). TES is 
conducted in an environment where drug administration is supervised, and then the 
results from the blood samples are assessed. Therapeutic efficacy studies are 
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prospective in terms of evaluating the patients’ clinical and parasitological responses after 
directly observed treatment for uncomplicated malaria. These studies assess resistance 
that regular intervals at the same sites to allow for early detection. The clinical and 
parasitological outcomes are assessed on the last day of the study, which would be either 
28 or 42 days, depending on the drug’s elimination half-life. If infections appear during 
the follow-up, the samples should be genotyped to determine if the infection are new 
infections or recrudescence. TES can help to determine the likelihood of antimalarial drug 
resistance, but additional tools, such as molecular marker analysis, need to be done to 
confirm the presence of drug resistance [28]. There are four possible outcomes of 
treatment with antimalarial drugs: early treatment failure, late clinical failure, late 
parasitological failure, and adequate clinical and parasitological response.  
Early treatment failure (ETF) can be suspected in situations that involve several 
possible conditions. One sign of ETF is the presence of danger signs or severe malaria 
on Day 1, 2, or 3 with parasitemia still present. Another sign is the existence of higher 
parasitemia on Day 2 than Day 0, regardless of axillary temperature. Also, the presence 
of parasitemia on Day 3 with an axillary temperature of greater than or equal to 37.5C 
and the existence of parasitemia on Day 3 that is greater than or equal to 25% of the 
count that was present on Day 0. There is an absolute requirement for a measured fever 
on Day 3 to classify the response as a failure because a fever of Day 2 happens 
frequently. If a history of fever in the preceding 24 hours were used as a condition on Day 
3, this would lead to an overestimation of the presence of early treatment failure. Further 
modifications to this definition include the requirement of a blood smear on Day 2. This 
change was made due to patient safety; waiting until Day 3 to get the first follow-up post-
treatment blood smear would be too long and could risk delays in treatment for patients 
with unresponsive parasitemia [29].  
Late clinical failure (LCF) is usually characterized by two main conditions. One is 
the existence of danger signs or severe malaria in the presence of parasitemia on any 
day between 4 to 28 (or Day 42, depending on the drug’s elimination half-life) in any 
patient who did not previously meet any of the criteria of early treatment failure. The other 
condition would be the existence of parasitemia between 4 and 28 days (or Day 42, 
depending on the drug’s elimination half-life) with an axillary temperature of greater than 
or equal to 37.5C in patients who did not previously meet any of the criteria of early 
treatment failure. There are some minor variations because of differences in the 
recommended duration of follow-up. These differ based on transmission in a specific 
area. For intense transmission areas, the follow-up is suggested to be 14 days. For low 
to moderate transmission areas, the follow-up period is 28 days. Also, in low to moderate 
transmission areas, a history of fever in the previous 24 hours can be used instead of a 
measured fever if requiring a measured increase in body temperature could cause logistic 
and financial hardship because of difficulty recruiting and enrolling patients [29].  
Late parasitological failure (LPF) is characterized by the presence of parasitemia 
on any day between 7 to 28 days (or Day 42, depending on the drug’s elimination half-
life) with an axillary temperature of less than 37.5C in any patients who did not previously 
meet any of the criteria of early treatment failure or late clinical failure. There are 
differences in this definition, depending on the transmission areas. This category is a 
recent addition. Prior to this, asymptomatic parasitemia after Day 4 was included as part 
of the adequate clinical and parasitological response, but it was deemed that information 
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on the parasitological failure frequencies is essential to understanding drug efficacy and 
should be accounted for [29].   
An adequate clinical and parasitological response (ACPR) is characterized by the 
absence of parasitemia on Day 28 (or Day 42, depending on the drug’s elimination half-
life) in patients who did not meet any of the criteria for early treatment failure, late clinical 
failure, or late parasitological failure, regardless of the axillary temperature of the patient 
[30]. The definition of this treatment outcome reconciles differences that existed in its 
previous definition by transmission intensity and is applied to only those responses that 
show both clinical and parasitological clearance by the end of the follow-up period [29].  
Some additional important concepts for therapeutic efficacy studies are adequate 
clinical response (ACR), total failure, and clinical failure. Adequate clinical response 
(ACR) is equal to the sum of those with an adequate clinical and parasitological response 
(ACPR) and those with late parasitological failure (LPF). Total failure is equal to the sum 
of those with early treatment failure (ETF), late clinical failure (LCF), and late 
parasitological failure (LPF). Clinical failure is equal to the sum of those with early 
treatment failure (ETF) and late clinical failure (LCF). The cut-off point for policy change 
using the WHO protocol in high transmission areas is when patients with ACPR is less 
than 75%, and patients with ACR is less than 85% [29].  
Failure in terms of malaria treatment may be because of infection with drug-
resistant parasites or bad absorption of the drug by the patient. A key measure of drug 
efficacy is the 50% inhibitory concentration (IC50). This measure is the concentration at 
which the antimalarial is able to inhibit the malarial parasite to 50% of its value in an 
untreated infection [31]. It is a useful parameter for monitoring in vitro resistance. 
Determining the IC50 of various antimalarials could be used to determine if resistance to 
drugs, especially those that are no longer the first-line treatment, decreases over time. If 
resistance does decrease, then there could be a possibility of reinstating previous first-
line treatments for uncomplicated malaria as treatment options again.  
Treatment failure of sulfadoxine-pyrimethamine can be associated with many 
potential causes. The presence of resistance-conferring mutations in the parasite is one 
reason. Another is the existence of high host folate levels. In a study where children were 
given folic acid supplements, these children had a higher treatment failure rate of SP 
when compared to a group of children who were given a placebo [32]. There may also be 
differences between individuals in terms of host pharmacokinetics. Variations in host 
pharmacokinetics include (a) the absorption rate of the drug, (b) where its distributed in 
the body, (c) how the tissue and plasma protein bind, and (d) the metabolism and 
excretion rates of the drugs. There all affect drug concentrations at active sites and are 
essential to determine the individual variability of therapeutic efficacy [33].  
In order to track the spread of antimalarial resistant alleles, countries can use 
molecular marker surveillance. This would allow policymakers to any possible changes 
before the failures of in vivo treatment reach a critical level. However, this is not routinely 
used. Researchers can also use this information to monitor resistance levels to stop 
usage when resistance to a particular treatment is high [8]. The sensitivities to various 
antimalarial drugs can be used to inform treatment as well as mass drug administration 
[2]. Molecular marker surveillance uses the prevalence of a particular antimalarial 
resistant alleles to determine the therapeutic efficacy of the antimalarial drug. The goal is 
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to incorporate what is known about in vivo efficacy with IC50 and molecular marker to 
improve the understanding of antimalarial drug resistance and to inform drug policy better.  
Hypothesis 1: When the samples were collected in Tanzania from 2003 to 2004, 
the first-line treatment of malaria was sulfadoxine-pyrimethamine (SP). Based on this, 
there may be a high level of prevalence of drug resistance polymorphisms related to the 
quintuple mutations (N51I, C59R, S108N in the DHFR gene and A437G, K540E in the 
DHPS gene).  
Hypothesis 2: Tanzania is a highly endemic area for malaria, which means there 
is an ongoing incidence of malarial infection and transmission in this population. Due to 
this, the follow-up samples may likely show high rates of clinical failure.  
The objectives of this study were to: (1) determine the prevalence of drug 
resistance polymorphisms at Day 0 in the 2003 – 2004 Tanzania sample, focusing on 
N51I, C59R, S108N in the DHFR gene and A437G, K540E in the DHPS gene; and, (2) 
and through genotyping determine whether the parasitological failure is a result of 
recrudescence or reinfection. There are three possibilities for the results of the follow-up. 
The first option is reinfection with a resistant strain. The second is a recrudescence of a 
resistant strain at a low frequency in the Day 0 population. The final option is the selection 















Age (years) 88 4.29 7.90 9.05 5.99 9.82 
Parasitemia 
(%) 




96 16,200 37,191.25 38,630.54 29,363.98 45,018.52 
 
 
 Male Female 




The samples for this study were collected from the Mlandizi Health Centre in the 
Kibaha coastal region in Tanzania. The region is about 40 kilometers northwest of Dar es 
Salaam. Malarial transmission in this area is perennial, so the incidence peaks occur 
during the end of the long rains, which is from May to July, and the short rains, which is 
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from December to January. Individuals who came to the center for treatment of 
uncomplicated Plasmodium falciparum malaria during 2003 to 2004 were tested using 
microscopy. Patients who tested positive and aged between six months and fifty-two 
years old were enrolled in the study. The Tanzanian Commission for Science and 
Technology approved these studies (Permit No. 2003-207-CC-2003-102). Information on 
follow-up and patient data can be found in Supplemental Table 1 in the Appendix. 
The sample consisted of 64% females and 36% males. The sample size of the 
ages was 88, and the median age was 4.29 years old. The average age of the participants 
was 7.9 years, with a standard deviation of 9.05 years of age (95% CI: 5.99, 9.82). The 
sample size of the parasitemia was 93, and the median of the parasitemia was 2%. The 
average parasitemia, or the percentage of red blood cells infected with the parasite,  was 
2.85%, with a standard deviation of 2.83% (95% CI: 2.27%, 3,43%). The sample size of 
the parasite densities was 96, and the median parasite density was 1.6 x 104 parasites 
per one microliter of blood. The average parasite density was about 3.7 x 104 parasites 
per one microliter of blood, with an estimated standard deviation of 3.8 x 104 parasites 
per microliter (95% CI: 2.9 x 104, 4.5 x 104). These descriptive statistics of the enrolled 
study population can be found in Table 1.  
 
Figure 1 Patient Flowchart: This figure shows the patients who were enrolled in the in 
vivo study, including those who were lost to follow-up and continued through to the end 




 After patients consented to enroll in the study, blood samples were collected from 
finger-pricks and stored on Whatman FTA filter papers before patients were treated with 
sulfadoxine-pyrimethamine (SP). Patients were asked to return to the clinic on Day 7 and 
Day 14 for follow-up or unscheduled if malaria-like symptoms returned. In the in vivo 
study, there were one hundred patients enrolled. On Day 7, twenty-seven patients were 
lost to follow-up, and seventy-three patients continued in the study. By day 14, an 
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additional 29 patients were lost to follow-up, and forty-four patients completed the study. 
On those who finished the study, forty-three cleared their parasitic load, and one patient 
had persistent parasitemia. Two of the forty-four patients also presented with persistent 
gametocytaemia. Figure 1 depicts the enrollment of the study. For the molecular marker 
study, seventy-seven Day 0 samples and thirty-five follow-up samples were to be used in 
this study. However, there were varying numbers of participants for each mutation, 




 The filter paper was used to extract genomic DNA via the QIAamp DNA Mini Kit 
(Qiagen) method. The protocol for filter paper samples was followed for all the samples 
in the study. 3 mm circles were punched out of from a dried blood spot on filter paper and 
added to a microcentrifuge tube with Buffer ATL, which lyses cells for use in nucleic acid 
purification. The tube was then incubated for at 85C to ensure complete lysis of the cells. 
Proteinase K was added, vortexed, and incubated at 56C. Proteinase K is used to digest 
contaminating proteins and degrade nucleases that may be present. This is to protect 
nucleic acids from being degraded by the nucleases. Buffer AL was then added to the 
sample to promote the lysis of the cell membrane and promote DNA isolation. Next, 
ethanol was added to the sample to remove the solvation shell around the DNA and allow 
for the precipitation of DNA in the pellet form. It also promotes the aggregation of DNA. 
The contents of the microcentrifuge tube were then added to a spin column and were 
centrifuged. Spin columns contain a silica resin that selectively binds DNA. The contents 
in the collection tube were discarded after centrifugation. Buffer AW1 was added to the 
spin column, and the tube was centrifuged. The purpose of Buffer AW1 is to denature 
proteins, so they are able to pass through the filter in the spin column. The contents of 
the collection tube were discarded again. Then Buffer AW2 was added to the spin column 
and centrifuged. Buffer AW2 is used to wash out the salts. The collection tube was 
discarded and replaced with a new one. The sample was centrifuged again to ensure that 
any possible Buffer AW2 carryover is eliminated. The spin-column was then placed in a 
microcentrifuge tube, and Buffer AE was added. The tube and spin-column were 
centrifuged. Buffer AE elutes DNA from the spin column membrane to the microcentrifuge 
tube to allow for the stable storage of the DNA. This step was repeated for a second 
elution. The extracted DNA for both Day 0 and follow-up samples were stored at –20C 
until tested by high resolution melting (HRM). 
 
High-Resolution Melting (HRM) 
 
 High resolution melting (HRM) is a method for single-nucleotide polymorphism 
(SNP) genotyping and mutation and sequence scanning in DNA samples. This 
technology characterizes nucleic acid samples based on how the double-stranded DNA 
separate and how the specific differences in a polymerase chain reaction (PCR) amplified 
sequences are detected by melting. Samples can also be distinguished by sequence 
length, GC content, and strand complementarity.  
 HRM analysis is a post-PCR method. A specific region of interest within the DNA 
sequence is first amplified using PCR. Special saturation dyes are added to the reaction, 
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so the only florescence present is of the double-stranded DNA. These dyes are called 
intercalating dyes. The amplified region of interest is called the amplicon. The amplicon 
concentration in the reaction tube increases as fluorescence releases by the double-
stranded amplified product increases. After the PCR is complete, HRM analysis starts. 
The amplicon DNA is heated up slowly from 50C to about 95C. At the temperature 
increases, the melting point of the amplicon is reached. When this point is reached, the 
DNA sample starts to denature, and the fluorescence from the dye is released, and it 
begins to fade away. At the start of the HRM analysis, there is a high level of fluorescence 
in the samples because there are many copies of the amplicon. However, as the sample 
continues to heat up, the two strands denature, so there is no more double-stranded DNA 
present, and fluorescence decreases. The HRM machine has a camera that measures 
the fluorescence while this process is happening. The process is then plotted on a graph 
known as a melt curve that shows the level of fluorescence versus temperature. 
 The temperature at which the DNA denatures is predictable. It is dependent on the 
sequence of the DNA bases. When comparing two samples, the shape of the melt curve 
should be exactly the same. However, a single base change in the sample DNA sequence 
can cause a difference in the HRM curves. Because different DNA sequences melt at 
different rates, these curves can be viewed and compared to determine similarities to a 
control.    
 This technique is very useful in a highly polygenomic population, such as 
Tanzania, for a variety of reasons. This method is accurate and has the ability to detect 
minor alleles [34]. HRM is also able to identify new genetic variants [35]. These variants 
could then be sent for sequencing to confirm that they are indeed new variants. HRM is 
a great tool for genotyping on a large scale because it is quick, inexpensive, and easy to 
deploy in the field. 
The reaction was performed on a LightScanner 96 using primers and probes for 
each specific mutation on a particular gene. A 96-well plate was used with a final well 
volume of 10 L. All reactions were done using 2.5 x LightScanner Master Mix, forward 
primers at a final concentration of 0.05 M, reverse primers at a final concentration of 
0.25 M, specific probes at a final concentration of 0.2 M, and 1 L of genomic DNA. 
The list of primers and probes can be found in Supplemental Table 2.  
 
Table 2 Reference Strains for HRM: Summary of reference strains used into assess 
the presence of each mutation.  
Mutation Reference Strain DNA Genotype Type 
DHFR 51 (N51I)   
3D7 A Wild-type 
DD2 T Mutant 
7G8 T Mutant 
TM90 A Wild-type 
DHFR 59 (C59R) 
3D7 T Wild-type 
DD2 C Mutant 
7G8 T Wild-type 
TM90 C Mutant 
DHFR 108 (S108N) 
3D7 G Wild-type 
DD2 A Mutant 
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FCR3 C Mutant 
DHPS 437 (A437G) 
3D7 C, G Wild-type 
DD2 T, G Mutant 
FCR3 C, C Mutant 
DHPS 540 (K540E) 
3D7 A Wild-type 
VS1 A Wild-type 
 
The standard software included with the LightScanner 96 was used to compare 
unknown probe peaks from samples with known probe peaks from reference strains. The 
reference strains differ depending on the gene. The experiments to assess the presence 
of the dhfr 51 and 59 mutations were combined. Four reference strains with known peaks 
were used: 3d7, Dd2, 7g8, and Tm90. For the presence of a mutation on dhfr 108, 3d7, 
Dd2, and Fcr3 were used as reference strains. To assess the existence of a mutation on 
dhps 437, 3d7, Dd2, and Fcr3 were also used as reference strains. As for dhps 540, 3d7 
and Vs1 were used as a reference. Table 2 shows the reference strains used for each 
experiment and the corresponding nucleic acid genotype.  
The melting peaks, that are based on different melting temperatures related to 
base pairing, were analyzed to call the specific genotypic mutations. Since the peaks of 
the reference strains are known, the sample peaks are compared to them. If the peaks 
match the wild-type reference strain, that sample is thought to have the wild-type 
genotype. If the peaks match the mutant strains, that sample is thought to have the mutant 
genotype. However, if the peaks match some combination of the two, that sample is 
thought to have a mixed genotype. At times, some peaks may not match any of the peaks; 
this could be an indication of a new mutation. HRM of the sample would then be repeated 
twice to ensure that this was a unique peak. After that, the sample would then be sent for 
sequencing to confirm if this was an indication of a new mutation.  
 
PCR Positivity by Plasmodium genus Primers 
 
Figure 2 Gel Electrophoresis of Follow-Up Samples: Gel of follow-up samples from 
Tanzania 
 
 18s rRNA gene was amplified using nested PCR. The PCR was carried out with a 
total volume of 20 L. This final volume included 10 L of GoTAQ, 1 L of each of the 
primers (PLU5 and PLU6), 6 L of reagent grade water, and 2 L of genomic DNA. The 
products were then analyzed on a gel, and their bands were compared. The reference 
strain 3D7 and reagent grade water was used as a positive control and negative control, 
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respectively. If the samples had the presence of bands similar to the reference strain, 
they were separated and tested by HRM to determine its drug resistance polymorphism.  
A 1% gel was made with agarose and TBE buffer and was left to set. Once the gel 
had been set, the DNA samples were loaded into wells. The power is then turned on, and 
the DNA fragments migrate through the gel based on their size, with larger fragments 
traveling a shorter distance than smaller fragments. Once the run has ended, the gel is 
placed under a UV light source that will display the DNA fragments at the bands for that 
distinct length. Figure 2 shows a gel that was run with the follow-up samples from 
Tanzania. There were thirty-five total samples run with two wells filled with the ladder 
located in the first well for each of the rows. However, positive and negative controls were 
not used. Based on where the band would have been had a positive control been used, 
there was one sample that was positive for parasites. This gel would need to be redone 




Table 3 Prevalence in Day 0 Samples for dhfr Gene: This tables shows the percent 
prevalence of each mutation on the dhfr gene. At position 51, the N51 denotes the 
presence of asparagine (N), which is the wild-type or the one that normally occurs in 
nature at that locus. 51I represents the presence of isoleucine (I), which is the mutant or 
the non-standard allele at position 51. N51+51I denotes a mixed infection at position 51, 
which means there was some combination of both the wild-type and mutant alleles. At 
position 59, the C59 denotes the presence of cysteine (C), which is the wild-type. 59R 
represents the presence of arginine (R), which is the mutant. C59+59R denotes a mixed 
infection. At position 108, the S108 denotes the presence of serine (S), which is the 
wild-type. 108N represents the presence of asparagine (N), which is the mutant. 
S108+108N denotes a mixed infection. 
Gene Allele 
Prevalence in Population 
Proportion Percentage 
DHFR 51 
(N = 52) 
N51 9/52 17.3% 
51I  26/52 50.0% 
N51 + 51I 17/52 32.7% 
DHFR 59 
(N = 52) 
C59  14/52 26.9% 
59R 22/52 42.3% 
C59 + 59R 16/52 30.8% 
DHFR 108  
(N = 75) 
S108  18/75 24.0% 
108N  52/75 69.3% 
S108 + 108N 5/75 6.7% 
 
The percent prevalence in completed Day 0 samples for the dhfr gene was found 
and can be viewed in Table 3. The prevalence of the asparagine to isoleucine mutation 
at the 51 position was 50% (N51I). This is associated with a DNA mutation of A to T. The 
prevalence of asparagine at the 51 position, the wild-type genotype, was 17.3%. The 
presence of mixed infections at the 51 position on the dhfr gene was 32.7%. The 
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prevalence of the cysteine to arginine mutation at the 59 position was about 42% (C59R). 
This corresponds to a mutation in DNA from T to G. The prevalence of a cysteine at the 
59 position, the wild-type genotype, was 26.9%. The presence of mixed infections at the 
59 position on the dhfr gene was 30.8%. The prevalence of the serine to asparagine 
mutation at the 108 positions was about 70% (S108N). This corresponds to a DNA 
mutation for G to either A or C. The prevalence of a serine at the 108 position, the wild-
type genotype, was 24.0%. The presence of mixed infections at the 108 position on the 
dhfr gene was 6.7%. 
 
Table 4 Prevalence in Day 0 Samples for dhps Gene: This tables shows the percent 
prevalence of each mutation on the dhps gene. At position 437, the A437 denotes the 
presence of alanine (A), which is the wild-type. 437G represents the presence of glycine 
(G), which is the mutant. A437+437G denotes a mixed infection. Undetermined is used 
to denote samples whose peaks did not match either the wild-type or mutant and 
needed to be sent for sequencing. At position 540, the K540 denotes the presence of 
lysine (K), which is the wild-type. 540E represents the presence of glutamic acid (E), 
which is the mutant. K540+540E denotes a mixed infection. 
Gene Allele 
Prevalence in Population 
Proportion Percentage 
DHPS 437 
(N = 50) 
A437 17/50 34.0% 
437G  14/50 28.0% 
A437 + 437G 12/50 24.0% 
Undetermined 7/50 14.0% 
DHPS 540 
(N = 50) 
K540  50/50 100% 
540E  0/50 0% 
K540 + 540E 0/50 0% 
 
The percent prevalence in completed Day 0 samples for the dhps gene was found 
as well and can be viewed in Table 4. The prevalence of the alanine to glycine mutation 
at the 437 position was 28% (A437G). This mutation corresponds to a DNA mutation of 
either C or G to T or C. The prevalence of an alanine at the 437 position, the wild-type 
genotype, was 34.0%. The presence of mixed infections at the 437 position on the dhps 
gene was 24.0%. 14.0% of the samples that had undetermined peaks at the 437 position, 
which were then sent for sequencing. The prevalence of the lysine at the 540 position 
was 100% (K540E). There were no samples with the lysine to glutamic acid mutation at 
the 540 position on the dhps gene. This is associated with a DNA mutation of A to T. 
There were also no samples with a mixed infection.  
 
Table 5 Prevalence in Day 0 Samples for Kelch Gene: This tables shows the percent 
prevalence of each mutation on the Kelch gene. At position 580, the C580 denotes the 
presence of cysteine (C), which is the wild-type. 580Y represents the presence of 
tyrosine (Y), which is the mutant. C580+580Y denotes a mixed infection. 
Gene Allele 
Prevalence in Population (N = 46) 
Proportion Percentage 
Kelch 580 C580 46/46 100% 
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580Y 0/46 0% 
C580 + 580Y 0/46 0% 
 
The percent prevalence of completed Day 0 samples for the Kelch gene was 
determined and can be view in Table 5. the prevalence of the cysteine to tyrosine 
mutations at the 580 positions was 0%. This corresponds to a mutation in DNA from G to 
A. The presence of cysteine at the 580 position on the Kelch gene is 100%. There were 
also no samples with a mixed infection. 
 
Figure 3 Summary of Mutations for Kelch, dhfr, and dhps Genes: This graph shows 
the percentage composition of the genotypes at each location. For dhfr51, the wild-type 
genotype is N51, mutant genotype is 51I, and mixed genotype is N51+51I. For dhfr59, 
the wild-type genotype is C59, mutant genotype is 59R, and mixed genotype is 
C59+59R. For dhfr108, the wild-type genotype is S108, mutant genotype is 108N, and 
mixed genotype is S108+108N. For dhps437, the wild-type genotype is A437, mutant 
genotype is 437G, and mixed genotype is A437+437G. Undetermined is used to denote 
samples whose peaks did not match either the wild-type or mutant. For dhps540, the 
wild-type genotype is K540, mutant genotype is 540E, and mixed genotype is 
K540+540E. For Kelch 580, the wild-type genotype is C580, a mutant genotype is 580Y, 
and the mixed genotype is C580+580Y. 
 
Figure 3 illustrates a summary of the mutations for the Kelch, dhfr, and dhps genes. 
In descending order, the highest rates of the wild-type genotypes were from Kelch 580, 
dhps 540, dhps 437, dhfr 59, dhfr 108, and, finally, dhfr 51. The greatest rate of the mutant 
genotype was at dhfr 108, followed by dhfr 51, then dhfr 59, and, finally, dhps 437. In 
terms of mixed infections, the highest rates in descending order of the completed samples 
were for dhfr 51, dhfr 59, dhps 437, and dhfr 108. dhps 437 was the only mutation that 
had samples that needed to be further sequenced in a lab to determine if that sample had 
a novel mutation. Both dhps 540 and Kelch 580 had no mutant alleles at their position in 




Table 6 Patient-Specific Genotypic Variation of Mutation Site (n = 50): This table 
provides a patient by patient view of the total mutants present of the quintuple 
mutations. Only patients’ samples that were tested for all five of the mutations were 
included in this table. For each mutation, the first letter represents the wild-type amino 
acid at that location. The number in the middle denotes the position where the mutation 
is located on the gene. The last letter indicates the mutant amino acid at that location. 
For example, for S108N, the location of the mutation is the 108 position on the dhfr 
gene. The wild-type amino acid at that location is serine (S), and the mutant amino acid 
is asparagine (N). Patients with mix showed peaks that aligned with both the wild-type 
and mutant alleles. Mix mut was used to distinguish patients whose samples’ peaks 
aligned with two different mutant alleles. Patients with triple mix showed peaks that 
aligned with wild-type and two mutant alleles. Other was used to classify those patients 
whose samples’ peaks did not align with any of the wild-type or mutant alleles. The 
mutant alleles for each patient were then summed and placed in the total mutations 
column.  
Sample 
DHFR DHPS Total 
Mutations S108N N51I C59R A437G K540E 
MLD 002 N I C Other K 2 
MLD 004 N Mix Mut Mix Mut Mix K 4 
MLD 005 Mix I R Mix K 4 
MLD 007 N I R A K 3 
MLD 013 N I R A K 3 
MLD 014 N I R A K 3 
MLD 017 N I R G K 4 
MLD 018 Mix Mix Mix Other K 3 
MLD 019 Mix Mix C A K 2 
MLD 020 N N C G K 2 
MLD 021 N I R A K 3 
MLD 022 N I R Triple Mix K 4 
MLD 023 N I C G K 3 
MLD 024 S N C Other K 0 
MLD 025 N I R A K 3 
MLD 026 N I C A K 2 
MLD 028 N Mix Mix A K 3 
MLD 029 N Mix Mix Mix K 4 
MLD 030 Mix N Mix Mut Mix K 3 
MLD 031 N I R G K 4 
MLD 034 N I C A K 2 
MLD 035 N Mix Mix Mix K 4 
MLD 036 N I R G K 4 
MLD 037 N Mix Mix Other K 3 
MLD 038 N I R Mix K 4 
MLD 039 N I R G K 4 
MLD 040 N Mix Mix Mix K 4 
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MLD 041 N I R G K 4 
MLD 043 N I R A K 3 
MLD 044 S N C G K 1 
MLD 049 N I R Mix Mut K 4 
MLD 050 S N C Other K 0 
MLD 051 N Mix Mut Mix Mut A K 3 
MLD 052 N I C G K 3 
MLD 054 Mix I R A K 3 
MLD 057 S N C A K 0 
MLD 063 N I R Mix K 4 
MLD 065 N I R Mix K 4 
MLD 069 S Mix Mix A K 2 
MLD 070 N I R Mix Mut K 4 
MLD 071 S N G G K 2 
MLD 077 N Mix Mix Other K 3 
MLD 078 N Mix Mix G K 4 
MLD 080 N Mix Mix A K 3 
MLD 081 S Mix Mix G K 3 
MLD 082 N I R Mix K 4 
MLD 096 N N R G K 3 
MLD 097 N Mix Mix G K 4 
MLD 098 N Mix Mix Other K 3 
MLD 099 N I R A K 3 
 
Table 6 describes the genotypic differences of each patient for each mutation on 
the dhfr and dhps gene. This table shows only those patients whose samples were able 
to be analyzed by HRM for all of the quintuple mutations. For the dhfr gene, 10% of the 
dataset had a wild-type allele at the 108, 51, and 59 positions. 90% of the samples had 
mutations at least one of these three locations. For the dhps gene, 32% of the dataset 
had a wild-type allele at the 437 and 540 positions. The remaining samples (68%) had 
mutations at the 437 position of the dhps gene. 0% of the samples had mutations at the 
540 position of dhps gene. For the samples that were complete, only 2% of the dataset 
had a wild-type allele for every mutation of the quintuple mutations. The rest of the 
samples (98%) had at least one mutation or other alleles for any of the five mutations. 
34% of the samples had at least four mutant alleles, 40% of the samples had three mutant 
alleles, 14% had two mutant alleles, and 2% had one mutant alleles. 36% of the samples 
completed were dhfr-triple mutant (three mutations present on the dhfr gene). 16% of the 
sample were dhfr-double mutants, and 26% were dhfr-single mutants. Finally, 18% were 
considered to be dhfr-wild-types. In terms of the dhps gene, 28% of the population were 
dhps-single mutants, and 32% were dhps-wild-types. In the completed samples, 42% had 
a mutant allele at the 59 position for the dhfr gene. 0% of the completed samples had a 
mutant allele at the 540 position on the dhps gene. A total of 0% of the completed sample 
had these two mutations. In the completed samples, there were about 70% of samples 
with a mutant allele at the 108 position of the dhfr gene. 28% of the completed samples 
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had a mutant allele at the 437 position of the dhps gene. A total of 22% of the completed 





 At the end of the study, there was one patient who was positive for 
gametocytaemia among the completed samples. Gametocytemia is the presence of 
gametocytes in the patient’s blood. Gametocytes are the form of the parasite that is able 
to transmit malaria to the mosquito vector [36]. A study conducted by Robert et al. found 
that post-therapeutic gametocytaemia was greater in patients that were treated with SP 
than those treated with chloroquine in terms of both prevalence and density [37]. With 
that in mind, it was not surprising to see one patient who was gametocyte-positive.  
In a review done by Naidoo et al., the uses and prevalence of resistant genotypes 
of sulfadoxine-pyrimethamine in Africa were discussed [38]. The review identified almost 
300 surveys that aimed to conduct surveillance of one or more of the dhfr or dhps 
mutations. The quintuple mutations (dhfr N51I, C59R, S108N, and dhps A437G and 
K540E) were the most common mutations surveyed. The prevalence of each mutation in 
Tanzania was provided. The prevalence of 51I, 59R, 108N, 437G, and 540E were about 
85%, 80%, 100%, 60%, and 50%, respectively. As stated above, the results of the current 
study differed from the review. For every mutation, the percentage in the review was 
greater than the percentage in the current study. However, the trends were similar, in that 
the review percentage was 1.5 to 2 times that of the current study. The current study 
experienced 108N genotype having the highest percentage of 69%, the review observed 
a 1.5 times greater value of 100%. 51I and 59R genotypes were close to each other and 
held the second and third highest percentages at 50% and 42.3%, respectively. The 
percentages in the review were about 1.7 to 1.9 times greater, at 85% and 80%, 
correspondingly. The 437G genotype was considered to be the second lowest percentage 
for the current study at 28%. The review, however, observed that 60% prevalence of this 
mutation, which was about double that of the current study. The review stated the 540E 
genotype had the lowest percentage at 50%, but it was non-existent in the completed 
samples of the current study. A reason for the existence of discrepancies between the 
studies is the number of samples in the studies. The review was using upwards of 4,000 
samples to determine the prevalence of each mutation; the current study used at most 75 
samples.    
Mutations in the Kelch gene are associated with artemisinin combination therapies 
(ACTs), which is the current first-line of treatment for uncomplicated malaria caused by 
the P. falciparum parasite by the World Health Organization (WHO) [39]. Since ACTs 
were not implemented in Tanzania as the first-line treatment until 2006, it would be 
expected that there should no mutations found. This would be due to the fact that there 
was no selective drug pressure for the ACT resistant genotype in 2003 when the samples 
were collected. Consequently, there were no 580Y genotypes in the completed samples.  
In a 2004 study, the therapeutic efficacy of sulfadoxine-pyrimethamine was 
assessed in Tanzania. High levels of SP resistance had already been documented in the 
northeast part of Tanzania since sulfadoxine was used as a therapeutic drug in 1994 [40]. 
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In the same region, pyrimethamine had also been used as a prophylactic in the 1950s 
[41]. 45% of patients in that region who were treated with SP failed to clear their 
parasitemia to low levels, which was a higher failure rate than other Tanzanian regions 
[42]. This provides a backdrop that suggested that after the implementation of SP as the 
first-line treatment in 2001, it would be likely that resistance would increase quickly. The 
results of this study showed that there was an association between treatment outcome 
(adequate clinical response, early treatment failure, late treatment failure) and the 
quintuple mutant genotype. The prevalence of the three mutation on the dhfr gene was 
four time greater at sites with high SP resistance than those with moderate SP resistance. 
The authors concluded that SP not be useful as the first-line treatment for malarial 
infection for a long period of time and that the triple pfdhfr mutant genotype may be used 
as an indicator of increasing resistance to SP [43]. 
The 2004 study also looked at molecular markers in five different regions of 
Tanzania: Butimba, Kyela, Mlimba, Masasi, and Mkuzi. Mkuzi is the region that would be 
the closest to where the current study’s samples were gathered from. In Mkuzi, there were 
127 samples collected. After molecular marker analysis, 80.3% of the population had 
three mutant alleles on the dhfr gene, 11.9% had two mutant alleles, and 2.4% had a 
single mutant. For the dhps gene, 32.3% of the population samples had two mutant 
alleles, and 13.4% had a single mutant. For wild-type alleles, 54.3% of the population 
possessed them on the dhps gene, and 5.5% possessed them on the dhfr gene. As 
mentioned earlier, the results in the current study concur with the 2004 study in that the 
largest percentage for the dhfr gene was for triple mutants. The double mutant percentage 
on the dhfr gene of both of the studies is comparable, with the current having a slightly 
higher percentage. However, the differences between the studies dominate. There was 
a greater percentage of single mutants on both the dhfr and dhps genes of the current 
study compared to the 2004 study. The percentage of wild-types on the dhfr gene in the 
current study was three times that on the study from 2004. The wild-type percentage of 
the dhps gene in the 2004 study were about one-third greater than that of the current 
study. These could be due in fact to the inability to finish conducting the molecular marker 
assays for the entire Day 0 samples. Another limitation could be the comparison between 
the Mkuzi region in the 2004 study and the Kibaha region in the current study. Although 
both regions are thought to have low malarial transmission, there are differences between 
the two regions in terms of parasite prevalence [44]. Perhaps this could explain the 
differences between the two studies. Additionally, the 2004 study did not include patients 
with mixed infections, which could have made a difference in the number of mutants 
present.  
In 2003, a study was conducted to assess the efficacy of SP in Tanzania as the 
first-line treatment for uncomplicated malaria [45]. On Day 14 of the study, the treatment 
failure rates were lower than the overall treatment failure rate prior to 2001. This study 
then extended the period of follow-up (28-day) in three sites in Tanzania. This resulted in 
about 50% of patients failing treatment. The authors also concluded that SP does not 
have high therapeutic value in Tanzania and recommended changing the first-line 
treatment to artemether + lumefantrine combination therapy. They also stressed that 
policy change in highly endemic areas should consider clinical and parasitological 
responses beyond 14 days. A limitation of the current study is that the follow-up points 
were Day 7 and Day 14. With an extended follow-up period of 21- or 28-days, the results 
18 
 
could have differed for this sample. The follow-up samples could have possibly shown 
more resistance has the number of days increased.  
A 2002 study aimed to move molecular assays to the forefront of tools for 
antimalarial drug resistance surveillance by accurately finding a subgroup of mutations 
that served as a reliable marker to predict SP treatment failure [46]. These researchers 
analyzed dhps and dhfr genotypes and related them to the treatment outcomes of 
patients. They found that a dhfr triple-mutant and dhps double-mutant were associated 
with SP treatment failure. In vivo resistance was associated with mutations at the 59 
position on the dhfr gene (C59R) and the 540 position on the dhps gene (K540E). 
However, as stated above, the current study did not have any samples that possessed 
both of those mutations. Additional research would be required to compare the two 
studies further. Treatment outcomes of the patients in the current study, including ETF, 
LCF, LPF, and ACPR, would need to be analyzed and compared to their dhps and dhfr 
genotypes. Also, since the entire sample could not be completed, it is difficult to make 




A limitation of this study is the lack of extended follow-up. The World Health 
Organization now recommends follow-up for 28 to 42 days to determine the efficacy of 
the antimalarial drug. Since SP has a long half-life, the recommended follow-up is 28 
days. Since the efficacy assessment was only based on 14 days in the current study, the 
level of parasite resistance could be underestimated. There was also no active follow-up, 
so there was a total of fifty-six patients lost to follow-up. One of the main reasons that 
patients may drop out of this study could be that after six days (for the 7-day follow-up) 
or thirteen days (for the 14-day follow-up), patients began to feel better, so they felt they 
did not need to come into the clinic to receive treatment anymore. Losses to follow-up are 
an issue because this reduces the effective sample size since the outcome measures of 
those who are lost are missing.  
Another limitation is the age of the sample of patients in the current study. The 
median age in Tanzania, as of 2020, is 18.2 years [47]. However, the median age of the 
present study was 4.29 years, which is not an accurate representation of the population 
of Tanzania. There were only thirteen participants above the age of eighteen in the 
present study. This would make it difficult to generalize the results of this study. The 
average age of the samples was 7.9 years old. In Tanzania, the age distribution of 
children is zero to fourteen years [48]. In the present study’s sample, this age range 
makes up about 85%. With that in mind, these patients would not be able to come into 
the clinic on their own to receive the antimalarial treatments. They would be required to 
have an adult with them to receive treatment. This could be another explanation for why 
many patients were lost to follow-up.  
The sex ratio for the current study is also a possible limitation. Tanzanian sex ratio 
as of 2020 for the male to female was 1.02, 1.01, and 1.01 for the 0 to 14, 15 to 24, and 
25 to 54 age groups [47]. Conversely, the overall male to female ratio of the present study 
was about 0.5. The ratio for 0 to 14 years was about 0.75. For both the 15 to 24 and 25 
to 54 age groups, there was no males present. Since the 0 to 14 age group males to 
female ratio of the current study were less than that of the corresponding overall 
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Tanzanian age group, this indicated that the samples had an abundance of females 
participating in the study. Considering that, it would be difficult to generalize the results to 
the whole Tanzanian population. 
 
COVID-19 Pandemic Situation 
 
The novel coronavirus was declared a Public Health Emergency of International 
Concern on January 30, 2020, by the WHO. This led to many states in the U.S. 
implementing shelter-in-place as a preventative measure. Yale University implemented 
university-wide closure on March 10th, citing that only essential personnel would be 
allowed on campus. At this time, the study was in the process of completing HRM of the 
Tanzanian Day 0 samples as well as conducting PCR and running a gel on the follow-up 
samples. This presented a challenge since the university closure led to the inability to 
access the laboratory to complete the HRM for all Day 0 samples and PCR-positive 




This study attempts to track the spread of antimalarial resistant alleles of 
sulfadoxine-pyrimethamine through molecular marker surveillance. Blood samples of 
patients from Tanzania were analyzed using high resolution melting (HRM), and their 
peaks were compared to reference strains. This would assist in determining the genotype 
of the mutations and its prevalence. The prevalence of 51I, 59R, 108N, 437G, and 540E 
was 50%, 42.3%, 69.3%, 28.0%, and 0%, respectively. Individual genotypes were 
reported for those samples that were completed for all of the quintuple mutations (n = 50). 
For the dhfr gene, 76% had a mutation at the 108 position, 52% had a mutation at the 51 
position, and 42% had a mutant allele at the 59 position. For the dhps gene, 28% had a 
mutant genotype at the 437 position, and 0% had a mutation at the 540 positions. Further 




Next steps for further research include the completion of HRM for the quintuple 
mutation polymorphisms on all of the blood samples in the 2004 Tanzania cohort as well 
as testing for PCR positivity for all of the follow-up samples. Based on the results of the 
PCR, barcoding or msp typing could be used to determine the genotype of the follow-up 
sample, depending on if the sample is monogenomic or mixed infection, respectively. This 
drug resistance typing will be used to determine if the resistance profiles of the follow-up 
samples differ from the respective Day 0 samples. Follow-up samples for the patients 
resulted in two patients with persistent parasitemia.  
There would have been two possible reasons for the follow-up samples’ results: 
recrudescence or reinfection. Recrudescence is the presence of the same parasitic 
genotype as the Day 0 sample. This could be due to treatment failure because of a variety 
of reasons, such as the difference in drug metabolism or patient compliance with the drug 
was too low to make it effective [49]. Although directly observed treatment is used to 
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improve compliance, patients can possibly skip coming into the clinic for their regular 
dosage. This would lead to a reduction in compliance. To evaluate this, the percent of 
follow-up completed would be analyzed for each patient that has had persistent 
parasitemia. If the percentage of follow-up completed was low, this could be an indication 
of decreased drug effectiveness due to the lack of compliance by the patient. Individual 
differences in drug metabolism could lead to limited metabolism, and therefore, 
decreased effectiveness of the antimalarial drug. To determine if this was the cause of 
recrudescence, the plasma clearance of each patient would be needed for analysis [50].  
Recrudescence could also occur because of antimalarial drug resistance. 
Compliance may contribute to drug resistance in that the lower drug levels in the blood 
allow the parasite to adapt and develop resistance to the antimalarial drug [51]. The 
presence of antimalarial drug resistance for these two samples would be tested by using 
HRM. As stated above, the primers and the probes for each mutation would be used to 
determine the genotype of the follow-up sample at each locus. This would be done by 
comparing the peaks of the follow-up strains to the reference strains to conclude if the 
sample had a wild-type, mutant, or mixed genotype. The follow-up samples’ genotypes 
would be compared to its corresponding Day 0 genotype. If the genotype types are 
similar, this would be an indication of recrudescence due to drug resistance.    
Reinfection is the identification of a different genotype from the Day 0 sample. The 
follow-up samples could have also been used to determine if the patients had early 
treatment failure (ETF), late clinical failure (LCF), late parasitological failure (LPF), or 
adequate clinical and parasitological response (ACPR). A sample would be considered 
to be LCF if its follow-up sample at Day 7 or Day 14 contained the presence of 
parasitemia, and the patient had a fever or signs of severe malaria. If a follow-up sample 
at Day 7 or Day 14 contained the presence of parasitemia, but the patient had no fever, 
this would be an indication of LPF. Prediction of ETF and ACPR would be difficult since 
the former would require a follow-up sample on Day 3, and the latter would require a 
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Appendix or Appendices 
 








Day 7 Day 14 
MLD 001 M 1.42 0.30% 2,280 --- --- 
MLD 002 M 0.83 1.06% 7,440  --- 
MLD 003 F 2.00 nr 5,920   
MLD 004 F 4.00 1.60% 25,440   
MLD 005 M 6.50 3.80% 6,000   
MLD 006 F 40.00 0.00% 4,800  --- 
MLD 007 F 7.00 7.10% 160,000 --- --- 
MLD 008 F 3.00 4.10% 128,000   
MLD 009 M 1.50 3.50% 88,000 --- --- 
MLD 010 F 1.75 5.80% 100,000   
MLD 011 F 5.17 4.80% 68,160   
MLD 012 F 4.50 2.20% 8,000   
MLD 013 F 13.00 1.60% 44,720   
MLD 014 F 20.00 1.03% 13,120   
MLD 015 F 4.00 2.20% 16,000 --- --- 
MLD 016 M 7.00 0.30% 5,200 --- --- 
MLD 017 M 2.50 3.00% 33,600  --- 
MLD 018 F 0.75 2.10% 80,000   
MLD 019 F 3.00 1.70% 60,000   
MLD 020 F 52.00 0.45% 4,280 --- --- 
MLD 021 M 4.25 2.00% 88,000  --- 
MLD 022 F 14.00 1.30% 9,600 --- --- 
MLD 023 M 1.00 3.30% 13,680 --- --- 
MLD 024 F 3.33 7.10% 76,000  --- 
MLD 025 F 17.00 2.20% 9,200 --- --- 
MLD 026 F 3.00 1.70% 16,000   
MLD 027 F 3.00 2.30% 17,040  --- 
MLD 028 F 17.00 1.30% 20,080   
MLD 029 F 2.25 11.00% 60,000   
MLD 030 M 6.00 3.10% 16,000  --- 
MLD 031 M 4.50 1.90% 48,000  --- 
MLD 032 M 0.58 na 43,520 --- --- 
MLD 033 F 1.75 10.00% 120,000 --- --- 
MLD 034 M  2.80% 52,000 --- --- 
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MLD 035 F 13.00 1.70% 16,400   
MLD 036 M 3.00 2.90% 80,080   
MLD 037 M 11.00 3.20% 80,000 --- --- 
MLD 038 M 1.42 2.20% 9,200 --- --- 
MLD 039 F 3.50 2.10% 96,000  --- 
MLD 040 F 22.00 1.10% 6,000  --- 
MLD 041 M  2.00% 6,400  --- 
MLD 042 M 8.00 0.02% 7,200 --- --- 
MLD 043 F 6.00 5.00% 80,000 --- --- 
MLD 044 F 11.00 0.90% 7,200   
MLD 045 F  0.01% 22,400 --- --- 
MLD 046 F 10.00 0.80% 4,880  --- 
MLD 047 F 5.17 4.60% 100,000  --- 
MLD 048 F 25.00 1.20% 8,000  --- 
MLD 049 F 14.00 0.40% 16,000  --- 
MLD 050 M 1.58 1.10% 10,000 --- --- 
MLD 051 F 32.00 1.00% 6,000   
MLD 052 F 3.00 7.50% 108,000   
MLD 053 F 2.00 15.80% 68,000 --- --- 
MLD 054 F 22.00 1.80% 6,000 --- --- 
MLD 055 F 14.00 0.80% 4,080 --- --- 
MLD 056 F 7.00 4.20% 17,600  --- 
MLD 057 F 4.00 9.00% 120,000  --- 
MLD 058 F 18.00 0.50% 2,800   
MLD 059 F 2.00 0.40%  --- --- 
MLD 060 F 3.42 3.70% 11,440  --- 
MLD 061 F 2.50  120,000 --- --- 
MLD 062 F 6.00 2.10% 6,480  --- 
MLD 063 M  1.00% 4,960   
MLD 064 F 18.00 0.10% 10,000  --- 
MLD 065 M 4.00 12.40% 100,000 --- --- 
MLD 066 F   34,000 --- --- 
MLD 067 M 0.50  60,000  --- 
MLD 068 F 20.00 0.01% 27,360  --- 
MLD 069 F 25.00 0.01% 4,640  --- 
MLD 070 M 7.00 1.70% 25,600  --- 
MLD 071 F 5.00 1.40%   --- 
MLD 072 M 4.00 7.00% 48,000  --- 
MLD 073 F 2.50  56,000   
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MLD 074 M 4.33 2.90% 5,360  --- 
MLD 075 F 5.00 3.70% 72,000 --- --- 
MLD 076 M 1.00 4.00% 60,000   
MLD 077 M 1.00 4.80% 80,000  --- 
MLD 078 F 1.00 2.10% 8,000 --- --- 
MLD 079 M  6.60% 100,000   
MLD 080 M 1.50 1.70%    
MLD 081 F 4.50 1.80%    
MLD 082 M  1.00% 23,200   
MLD 083 M 3.50 5.20% 120,000  --- 
MLD 084 F 18.00 3.50% 6,120   
MLD 085 F  1.00% 60,000   
MLD 086 F  2.50% 9,040   
MLD 087 M 4.00 1.20% 50,240   
MLD 088 M 5.50 0.60% 14,720   
MLD 089 F 19.00 1.90% 23,040   
MLD 090 F   6,240   
MLD 091 M 0.50 0.70% 5,200   
MLD 092 F  3.50% 6,000   
MLD 093 F 3.25 2.40% 8,000   
MLD 094 F 3.25 7.50% 6,400   
MLD 095 M 1.75 2.60% 9,040   
MLD 096 M 6.00 1.10% 7,440   
MLD 097 F 2.00 1.50% 23,280   
MLD 098 F  2.00% 4,400   
MLD 099 F 6.50 1.70% 16,000   
















Supplemental Table 2 Primers and Probes for HRM: These are the DNA sequences 
of the primers and probes used the HRM experiments. The 3’ bold base pairs in the 
probes represent mismatched bases to ensure that amplification using the probe as a 
template does not occur. 
Gene Mutation Sequence (5’→ 3’) 
DHFR 
S108N 
Forward 
Primer 
CTGTGGATAATGTAAATGATATGCCTAATTCTA 
Reverse 
Primer 
GACAATATAACATTTATCCTATTGCTTAAAGGT 
Probe GGAAGAACAAgCTGGGAAAGCATGA 
N51C/ 
C59R 
Forward 
Primer 
ACATTTAGAGGTCTAGGAAATAAAGGAGT 
Reverse 
Primer 
ATATTTACATCTCTTATATTTCAATTTTTCATATTTTGATTCATTCAC 
Probe AAATGTAaTTCCCTAGATATGAAATATTTTtGTGCAGCC 
I164L 
Forward 
Primer 
ACAAAGTTGAAGATCTAATAGTTTTACTTGGG 
Reverse 
Primer 
CTGGAAAAAATACATCACATTCATATGTACTATTTATTCTA 
Probe AATGTTTTATTaTAGGAGGTTCCGCC 
DHPS 
A437G 
Forward 
Primer 
GAATGTTTGAAATGATAAATGAAGGTGCTA  
Reverse 
Primer 
CAGGAAACAGCTATGAC 
GAAATAATTGTAATACAGGTACTACTAAATCTCT  
Probe ATCCTCTGGTCCTTTTGTTATACCGG 
K540E 
Forward 
Primer 
GTGTTGATAATGATTTAGTTGATATATTAAATGATATTAGTGC 
Reverse 
Primer 
GTTTATCCATTGTATGTGGATTTCCTCTT 
Probe TAATCCAGAAATTaTAAAATTATTAAAAAAAAAAAACGG 
A581G 
Forward 
Primer 
CTTGTATTAAATGGAATACCTCGTTATAGGA 
Reverse 
Primer 
AGTGGATACTCATCATATACATGTATATTTTGTAAG 
Probe TTGGATTAGGATTTGcGAAGAAACATGATCACC 
A613T/S 
Forward 
Primer 
CTCTTACAAAATATACATGTATATGATGAGTATCCACTT 
Reverse 
Primer 
CATGTAATTTTTGTTGTGTATTTATTACAACATTTTGA 
Probe AAGATTTATTgCCCATTGCATGACC 
CRT 
H97Q 
Forward 
Primer 
TTTGCTAAAAGAACTTTAAACAAAATTGGTAACTA 
Reverse 
Primer 
ATTTATCTTACTTTTGAATTTCCCTTTTTATTTCCA 
Probe CATACAAATAAAGTTgTGAGTTTCGGATGTTACCC 
K76T 
Forward 
Primer 
GTAAAACGACGGCCAGTTTCTTGTCTTGGTAAATGTGCTCA 
Reverse 
Primer 
CAGGAAACAGCTATGACCGGATGTTACAAAACTATAGTTACCAAT 
Probe GTGTATGTGTAATGAATAAAATTTTTGAC 
A220S 
Forward 
Primer 
gctcaggtcgTTGAAACACAAGAAGAAAATTCTATC 
Reverse 
Primer 
gctcaggtcgAAACAAAGTTTAAGTGTTAATATATATTAAATATTAC 
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Probe GTCTTAATTAGTgCCTTAATTGTACT 
N326S/D 
Forward 
Primer 
cgagcaTTTTTTAGAAAACCTTCGCATTGT 
Reverse 
Primer 
TTCATCCTTTTTATTCTTACATAGCTG 
Probe CTTCTTTgaCATTTGTGATAATTCC 
I356T/L 
Forward 
Primer 
gctcaggtcgAAATTTTCTACCATGACATATACTATTG 
Reverse 
Primer 
cacctgactgaTTTATATATTTATATCTTTTTAATTCTTACGGC 
Probe GTCCAGCAacAGCAATTGCTCC 
Kelch C580Y 
Forward 
Primer 
GGCACCTTTGAATACCC 
Reverse 
Primer 
CATTAGTTCCACCAATGACA 
Probe AGCTATGTGTATTGCTTTTGAT 
 
